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Matrine, a clinical drug in China, has been used to treat viral hepatitis, cardiac arrhythmia and skin inflammations.
Matrine also exhibits chemotherapeutic potential through its ability to trigger cancer cell death. However, the
mechanisms involved are still largely unknown. The objective of this study was to investigate the major determinant for
the cell death induced by matrine in human hepatocellular carcinoma. We use human hepatocellular carcinoma cell
line HepG2 and human hepatocellular carcinoma xenograft in nude mice as models to study the action of matrine in
hepatocellular cancers. We found that caspase-dependent and -independent Program Cell Death (PCD) occurred in
matrine-treated HepG2 cells, accompanied by the decreasing of mitochondrial transmembrane potential and the
increasing ROS production. Further studies showed that AIF released from the mitochondria to the nucleus, and
silencing of AIF reduced the caspase-independent PCD induced by matrine. What’s more, AIF nuclear translocation, and
the subsequent cell death as well, was prevented by Bid inhibitor BI-6C9, Bid-targeted siRNA and ROS scavenger Tiron.
In the in vivo study, matrine significantly attenuated tumor growth with AIF release from mitochondria into nucleus
in nude mice. These data imply that matrine potently induce caspase-independent PCD in HepG2 cells through
Bid-mediated AIF translocation.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy [1], and the third cause of cancer-related
mortality worldwide [2]. The overall incidence of HCC is
fairly high and steadily rising in both the developed and
the developing world, on account of the prevalence of the
two major risk factors, hepatitis B virus (HBV) and hepa-
titis C virus (HCV) [3]. Despite the poor understanding of
how HBV and/or HCV lead to HCC, some antiviral agents
have been found to exhibit anticarcinogenic effects [4].
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teritis, hepatitis, hepatic fibrosis and hypertension in
China [5]. Matrine is also found to induce cell death in
many kinds of cancer cells, including cervical cancer,
leukemia, gastric cancer, lung cancer and breast cancer
[6-10], and thus is considered as a promising drug for
cancer therapy.
Caspase-dependent apoptosis is the best-known mo-
dality of programmed cell death (PCD) [11]. Conven-
tional anticancer agents, regardless of their distinct
targets and mechanisms, primarily induce cell death via
caspase-dependent apoptosis [12,13]. Meanwhile, cancer
cells are usually sensitive to caspase-dependent apoptotic
induction initially, but eventually they become drug-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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manifested as the over-expression of anti-apoptotic pro-
teins and the defects in pro-apoptotic factors [14,15].
Therefore, developing new drugs and methods that can
specifically treat drug-resistant cancers is an urgent task
for saving lives.
Fortunately, increasing evidence shows that PCD can
also happen in the presence of the pan-caspase inhibitor
z-VAD-fmk [16,17]. In C. elegans, some cells succumb to
developmental cell death in a caspase-independent path-
way [18]. N-methyl-N’-nitro-N-nitrosoguanidine (MNNG)
can also induce caspase-independent PCD (ciPCD) in
MEF cells [19]. However, understanding of how cells
actually die during ciPCD remains limited. Recently,
strong evidence of the important role of AIF in ciPCD, via
its releasing from mitochondria into nucleus [20,21],
has been shown in studies performed with alkylating
DNA damage agents [22,23]. Despite the prominent
role of AIF in ciPCD signaling, the mechanisms up-
stream of AIF releasing are still poorly defined. Previous
studies have suggested that a member of the bcl-2
family, Bid, facilitates the insertion of Bak or Bax into
mitochondrial membrane to form functional oligo-
mers, which results in the depolarization of the inner
mitochondrial membrane and the subsequent AIF
translocate from mitochondria to nucleus [24,25].
Thus, Bid regulates AIF translocation is involved in
ciPCD, and might be a potential mechanism for de-
veloping effective drug to induce cancer cell death.
HepG2 cell line is well characterized of hepatocellular
carcinoma and is widely used in the study [26,27].
Therefore, we investigated the mechanisms of matrine-
induced cell death in hepacellular carcinoma cell line
HepG2 in vitro and subcutaneous xenograft tumors in
nude mice in vivo. We found that caspase-dependent
and caspase-independent PCD occurred in HepG2,
accompanied by mitochondrial transmembrane po-
tential losing, ROS production, cytochrome c and AIF
released from the mitochondria. What’ more, AIF was
required in caspase-independent cell death and its
translocation was prevented by Bid inhibitor BI-6C9,
Bid siRNA and ROS scavenger Tiron. In the in vivo
study, matrine significantly attenuated tumor growth
with AIF release from mitochondria and accumulation
in nucleus in nude mice. These findings suggest that
matrine may provide a new selectivity for hepatocarci-
noma therapy through the induction of AIF-mediated
ciPCD.
Results
Matrine induced caspase-dependent and -independent
PCD in HepG2 cells
To investigate the mode of cell death induced by matrine
(structure in Figure 1A) treatment in HepG2 cells, flowcytometry was employed. Results showed that the cell death
rate was increased in both dose- and time-dependent
manners (Figure 1B & Additional file 1: Figure S1A),
with the decreasing of mitochondrial transmembrane
potential (ΔΨm) (Figure 1C & Additional file 1: Figure S1B)
and the releasing of cytochrome c from mitochondria
(Figure 1D). These results are consistent with previous
report in AML cells [9] and our other results in QBC939
(Xu and Hu, unpublished data). Additionally, matrine
treatment increased the levels of apoptosis-related pro-
teins Fas and Fas-L and the cleaved caspase-3, while de-
creased the levels of procaspase-8, procaspase-9 and
procaspase-3 (Figure 1E). Notably, the pathways of cell
death induced by matrine include caspase activation.
Cell death can also happen through an alternative mito-
chondrial pathway, which is independent of caspase acti-
vation [20]. To elucidate whether the caspase-independent
pathway was also involved in the matrine-induced cell
death, a pancaspase inhibitor z-VAD-fmk (Calbiochem),
which completely inhibited the caspase-dependence
of TNF-induced cell death in A cells [28] and TNF/cy-
cloheximide-induced cell death in colon tumour cells
[23], was used. The results showed that cell death in-
duced by matrine was partly suppressed by z-VAD-fmk,
compared with the control group (Figure 1F & Additional
file 1: Figure S1C). Thus, we can conclude that matrine-
induced cell death through caspase-dependent and
-independent pathway in HepG2 cells.AIF translocation is required for matrine-induced ciPCD in
HepG2 cells
AIF was reported to play important roles in ciPCD [20].
To further study how matrine induce ciPCD in HepG2
cells, we knocked down endogenous AIF in HepG2 cells
by transfecting AIF-targeted siRNA (Figure 2A). We found
that down-regulation of AIF expression effectively attenu-
ated matrine-induced ciPCD in HepG2 cells, compared to
the cells transfected with a non-targeted siRNA (Figure 2B
& Additional file 2: Figure S2), indicating the important
role of AIF in matrine-induced ciPCD.
The translocation of AIF from the mitochondria to
the nucleus is required for its activation in ciPCD
[29], so we combined immunostaining and cell frac-
tionation methods to detect whether matrine affected
the subcellular location of AIF. DAPI was used to
stain nucleus. AIF showed a granular pattern in the
mitochondria, whereas after treatment with matrine,
AIF was detected in the nucleus (Figure 2C). More-
over, we confirmed AIF location by western blot ana-
lysis of fractioned cellular components (Figure 2D).
These results indicated that AIF release to the cyto-
plasm and translocate to the nucleus by matrine treat-
ment in HepG2 cells.
Figure 1 Matrine induced caspase-dependent and -independent cell death in HepG2 cells. (A) The chemical structure of matrine. (B) Cells
were treated with different concentrations of matrine (0, 0.25, 0.5, 1, 1.5, 2 mg/ml) for 24 hrs, or 1.5 mg/ml matrine for different time periods (0, 12, 24,
36, 48 hrs), and then the cell death was determined by Annexin V/PI staining assay. (C) Cells were collected after treated with different concentrations
of matrine for 24 hrs and analyzed for ΔΨm by Rh123 retention. (D) Expression of cytosolic and mitochondrial cytochrome c in HepG2 cells with
matrine treatment. Cells were treated with 1.5 mg/ml of matrine for 24 hrs. The cytoplasmic and mitochondrial proteins were segregated and analyzed
by western blot assay. (E) HepG2 cells were treated with different concentrations of matrine for 24 hrs. The total protein was extracted and the expres-
sion of apoptosis-related proteins was analyzed by western blot assay. (F) Effect of pancaspase inhibitor, z-VAD-fmk, on matrine-induced cell death.
HepG2 cells were pretreated with z-VAD-fmk (20 μM, 2 hrs) before matrine treatment. Cell death was analyzed by Annexin V/PI staining assay. Data are
presented as means ± S.D. of three separate experiments. The basal level of cell death was normalized to 1. *p < 0.05, **p < 0.01 vs. control.
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translocation
How is AIF activated by matrine in HepG2 cells? A ma-
nuscript has already described that Bid regulates AIF-
mediated caspase-independent necroptosis [25]. Thus, we
transfected HepG2 cells with Bid siRNA or pretreated
with Bid inhibitor (Santa Cruz Biotechnology), and then,
analyzed AIF location by immunostaining and westernblotting. Down-regulation of Bid expression significantly
reduced matrine-induced AIF nuclear translocation in
HepG2 cells (Figure 3A). Moreover, BI-6C9 also blocked
matrine-induced AIF translocation detected by confocal
microscopy (Figure 3B). The findings were confirmed with
the results from western blotting (Figure 3C & 3D). We
can conclude that Bid was required for matrine-induced
AIF release from the mitochondria to the nucleus.
Figure 2 AIF translocation is required for matrine-induced ciPCD. (A-B) HepG2 cells were transfected with AIF siRNA (40 or 60 nM) or non-
targeted siRNA for 24 hrs, and then treated with matrine at 1.5 mg/ml for 24 hrs. (A) AIF expression levels were detected by western blot analysis
using an anti-AIF antibody. Actin was used as a protein loading control. (B) Cells were stained with Annexin V/PI to assess cell viability by flow
cytometry. The basal level of cell death was normalized to 1.*p < 0.05, **p < 0.01 vs. non-target siRNA+Matrine. (C) Immunostaining was performed
to localize AIF with an anti-AIF antibody and a FITC-conjugated secondary antibody (green). The nuclei were detected using DAPI staining (blue).
(D) Cytoplasmic, nuclear, and mitochondrial fractions were prepared for western blot analysis using anti-AIF, anti-β-tubulin (cytosolic marker), anti-Hsp60
(mitochondrial marker) and anti-Lamin B (nuclear marker) antibodies.
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death induced by matrine in HepG2, we performed flow
cytometry analysis. Down-regulation of Bid expression
attenuated matrine-induced cell death by transfecting
Bid siRNA (Figure 3E & Additional file 3: Figure S3A).
In addition, Bid inhibitor BI-6C9 was applied to confirm
the essential role of Bid in cell death induced by matrine.
Pretreatment with BI-6C9 rescued matrine-induced cell
death in HepG2 (Figure 3F & Additional file 3: Figure
S3B). Thus, activation of Bid may serve a mechanism by
which matrine induces PCD through regulation of AIF
nulear translocation in HepG2 cells.The role of AIF in matrine-induced cell death partly occurs
through increasing energy metabolism-associated ROS
production in HepG2
The apoptosis/necrosis should at least partly occur
through increasing energy metabolism-associated ROS
production [28]. ROS served as a possible upstream or
downstream mediators of cell death [30]. Thus, we de-
tected ROS production using dihydroethidium (Molecu-
lar Probe), a cell-permeable fluorescence dye that reacts
with a broad spectrum of ROS. Flow cytometry assay
shows that matrine treatment increase ROS production
in a dose-dependent manner (Figure 4A & Additional
Figure 3 Bid mediated the cell death induced by matrine, as an upstream regulator of AIF. HepG2 cells were transfected with Bid siRNA
(40 or 60 nM) or non-targeted siRNA for 24 hrs (A, C, E) or pretreated Bid inhibitor BI-6C9 (10 μM) for 1 hr (B, D, F), then treated with matrine at
1.5 mg/ml for 24 hrs. (A, B) Immunostaining was performed to localize AIF with an anti-AIF antibody and a FITC-conjugated secondary antibody
(green). The nuclei were detected using DAPI staining (blue). (C, D) Cytoplasmic, nuclear, and mitochondrial fractions were prepared for western
blot analysis to localize AIF with an anti-AIF antibody using anti-AIF, anti-β-tubulin (cytosolic marker), anti-Hsp60 (mitochondrial marker) and
anti-Lamin B (nuclear marker) antibodies. (E, F) Cells were stained with Annexin V/PI to assess cell viability by flow cytometry. The basal level of
cell death was normalized to 1.*p < 0.05, **p < 0.01 vs. non-target siRNA + Matrine (E), Matrine (F).
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Figure 4 ROS production is required for AIF activation in HepG2 cells. (A, B) Cells were treated with matrine at different concentrations (0,
0.25, 0.5, 1, 1.5, 2 mg/ml) for 24 hrs or at 1.5 mg/ml for 24 hrs in the absence or presence of Tiron (5 μM), the ROS scavenger. ROS levels were
then detected by flow cytometry. (C) Tiron significantly attenuated matrine-induced cell death as determined by Annexin V/PI staining and flow
cytometry. The basal level of cell death was normalized to 1.*p < 0.05, **p < 0.01 vs. Matrine. Immunostaining (D) and western blot analyses (E)
demonstrated that matrine-induced AIF translocation to the nucleus was inhibited by Tiron.
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ition of ROS influenced matrine-mediated cell death. Pre-
treatment with a cell permeable ROS scavenger, Tiron
(Santa Cruz Biotechnology), blocked ROS generation and
attenuated cell death induced by matrine (Figure 4B, C &
Additional file 4: Figure S4B, C ), suggesting that ROS
generation could mediate PCD induced by matrine in
HepG2 cells.
To investigate the role of ROS in AIF activation, pre-
treatment of HepG2 cells for 24 hrs with Tiron. We com-
bined immunofluorescence and cell fractionation methods
to detect the AIF location. Immunofluorescence results
show that Tiron inhibited matrine-induced AIF translocatefrom mitochondria into nucleus (Figure 4D). Moreover,
we confirmed this finding by western blotting of frac-
tioned cellular components (Figure 4E).
Matrine inhibits the proliferation of HepG2 cells in the
nude mice
We established the model of hepatocellular carcinoma
cells xenograft in nude mice by injecting HepG2 cells.
When the tumors reached around 0.120 cm3, the mice
were randomly assigned to five groups to receive intra-
peritoneally injection of saline (negative control), 50, 75,
100 mg/kg of matrine, or 50 mg/kg of cyclophosphamide
(positive control) every two days. As show in Figure 5A-D,
Figure 5 Matrine inhibits the proliferation of HepG2 cells in nude mice. (A, B) Typical photographs of tumor samples from the nude mice
treated with different doses of matrine. HepG2 cells were implanted by subcutaneous injection into the right fore leg of the nude mice. Different
doses of matrine were administered to the mice by subcutaneous injection every other day. Mice in control group were given physiological
saline alone. After 3 weeks, the mice were sacrificed. (C, D) Volume and Weight of tumor samples from nude mice treated with different doses of
matrine. Data are reported as means ± S.D. of three separate experiments. *p < 0.05, **p < 0.01 vs. control. (E) Subcellular location of AIF in tumor
samples from the control group and the 100 mg/kg matrine-treated group were analyzed by immunohistochemistry.
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mice.
The subcellular location of AIF in the subcutaneous
tumor tissues were further examined by immunohisto-
chemical staining. AIF located in the cytoplasm in the
tumors from negative control group, while tumors
from 100 mg/kg matrine treatment group showed apredominantly nuclear localization of AIF (Figure 5E),
in accordance with the results of HepG2 cells treated
with matrine in vitro.
Discussion
Many traditional Chinese medicine and related active
compounds have been reported to have potent anti-cancer
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that the anti-carcinogenic property of matrine is closely
associated with inhibition of proliferation and induction of
apoptosis [6-8]. Matrine induces apoptosis in U937 cells
and K562 cells via the mitochondrial pathway, a cyto-
chrome c-triggered caspase activation pathway [9,31]. In
accordance with previous observations in a variety of
tumour cell lines, we found that matrine induced cell
death partly through the caspase-dependent pathway in
HepG2 cells. The matrine-induced cell death in HepG2
cells appeared to accompany with the release of cyto-
chrome c, ROS and AIF, together with the decreasing of
mitochondrial transmembrane potential, which indicate
a critical role for mitochondria in matrine-induced cell
death. It is worth notice that cytochrome c is involved
in caspase-dependent pathway, ROS and AIF are mostly
associated with caspase-independent pathway [20], so we
tested if caspase independent pathway is also involved. As
expected, we found that z-VAD-fmk, an inhibitor of
caspase activation, did not block all of cell death upon
matrine treatment in HepG2 cells, suggesting the exist-
ence of ciPCD. ROS generation may be a critical in-
ductor in matrine-induced ciPCD because the free
radical scavenger Tiron blocked both cytotoxicity and
AIF mitochondria-nucleus translocation. Thus, matrine
induced concomitantly caspase-dependent and caspase-
independent death in HepG2 cells.
The discovery and understanding of ciPCD will open
new perspectives for the treatment of tumor. On the one
hand, the existence of caspase-independent pathways
provides new options to kill tumor cells [23,32], and one
of such therapies has already advanced into clinical trials
[33,34]. On the other hand, because the anti-apoptotic
mechanisms that suppress caspases activation have also
been shown to be involved in drug resistance of tumor
cells [15,35], combination of caspase-directed and alter-
native therapies based on caspase-independent death
effectors will provides a more efficient approach to cir-
cumvent the commonly observed therapy resistance of
transformed cells.
It was reported that truncated Bid (tBid), the cleaved
and active form of Bid, translocates to the mitochondria
and activates Bax/Bak homooligomerization in the outer
mitochondrial membrane, followed by the release of AIF
from mitochondria in MNNG-induced ciPCD [24]. We
did found that matrine decreased the levels of Bid in the
cytosol and the nucleus (data not shown), inferring the
cleavage of Bid into tBid. However, the mitochondrial Bid
did not obvious increased under our experimental condi-
tions (data not shown), which might be due to the short
half-life of tBid. And we further found that transfected
HepG2 cells with Bid siRNA or pretreated with Bid inhibi-
tor prevented matrine-induced AIF nuclear translocation.
Recently, necroptosis, a parallel but nonapoptotic pathwayof cell death, has been described [36-38]. After MNNG
treatment, PARP-1 activation stimulates the release of
AIF from the mitochondria [39,40], which depends on
calpain Cys proteases and the proapoptotic Bcl-2
member Bid and Bax [24,25]. And then AIF rapidly
translocalizes to the nucleus, in cooperation with his-
tone H2AX [19,22] and cyclophilin A [41], provokes
caspase-independent necroptosis [20]. Moreover, ROS
is essential for this type of cell death [28]. Matrine
induced ciPCD through Bid-mediated AIF nuclear trans-
location and ROS production were in accord with the sig-
naling pathway of MNNG-induced caspase-independent
necroptosis. Therefore, the signaling pathway of MNNG-
induced caspase-independent necroptosis might be the
mode of cell death HepG2 cells following treatment with
matrine.Conclusion
The present studies demonstrated that matrine can
induce concomitantly caspase-dependent and caspase-
independent cell death in HepG2 cells through Bid-
regulated AIF (the best studied example of a ciPCD
mediator) nuclear translocation pathway. The eluci-
dation of the mechanism of matrine-induced ciPCD
suggests a possible therapeutic role of matrine and its
potential of combination with other chemotherapies
targeting caspase-dependent pathway to treat heptacel-
lular carcinoma.Methods
Cell culture
The human hepatocellular carcinoma cell line HepG2
(obtained from Shanghai Institute of Cell Biology, Chinese
Academy of Sciences, Shanghai, China) were cultured
in DMEM supplemented with 10% fetal bovine serum,
penicillin-streptomycin, in a humidified 5% CO2 atmos-
phere. The HepG2 cells in mid-log phase were used in
experiments. Matrine was purchased from Sigma Chem-
ical Co. (St. Louis, MO, USA), dissolved in distilled water
at a concentration of 50 mg/ml as a stock solution and
stored at 4°C in the dark.Transient transfection of siRNA
Bid siRNA, AIF siRNA and nonfunctional control siRNA
were purchased at Santa Cruz Biotechnology. HepG2
cells were transfected with non-targeted, Bid siRNA or
AIF siRNA using Lipofectamine 2000 (Life Technology,
Carlsbad, CA, USA), according to the manufacturer’s in-
structions. After 24 hrs transfection, cells were treated
with matrine in serum-starved medium for 24 hrs for
cell death assay and western blot analysis to determine
the expression level of AIF.
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We used Annexin V-FITC (0.1 mg/ml) for the assess-
ment of phosphatidylserine exposure, propidium iodide
(PI, 0.5 mg/ml) for cell viability analysis, Rh123 (50 nM)
for DCm quantification and DCFH-DA (10 μM) for de-
tecting ROS production. The samples were analyzed by
flow cytometry (Becton Dickinson FACS can).
Immunostaining
After matrine treatment, cells were washed with PBS
and fixed with 4% paraformaldehyde for 15 min at room
temperature. Cells were permeabilized using 2% Triton
X-100 for 5 min in PBS at room temperature and blocked
in 3% bovine serum albumin in PBS containing 1% Triton
X-100 for 1 hr at room temperature. Slides were then in-
cubated with goat monoclonal antibody against AIF (1:50)
over night at 4°C. The cells were then washed and sub-
sequently incubated with both FITC-conjugated rabbit
anti-goat secondary antibodies at a dilution of 1:50 for
1 hr at room temperature. Cells were mounted in anti-
fade solution onto glass slides and observed under
confocal microscopy.
Cytosolic, nuclear and mitochondrial protein isolation
After matrine treatment, cells were collected and re-
suspended in five volumes of ice-cold extract Buffer
A (20 mmol/L HEPES-KOH, pH7.5, 1.5 mmol/L Mg-
Cl2,1 mmol/L EDTA,1 mmol/L EGTA,1 mmol/L DTT,
0.1 mmol/L PMSF) and were homogenized. The ho-
mogenates were centrifuged at 1000 × g for 10 min,
4°C. The supernatant was collected and centrifuged
at 10,000 × g for 15 min, to obtain the mitochondria
pellets (resuspended in 100 μL Buffer A). The superna-
tants were further centrifuged at 100,000 × g for 1 hr
(4°C) to collect the cytosolic fraction. For the isolation
of the nuclear proteins, ice-cold extract NE-Buffer A
(10 mmol/L HEPES, pH7.9, 1.5 mmol/L MgCl2,10 mmol/L
KCl, 0.5 mmol/L DTT, 0.5 mmol/L PMSF) was added to
the pellet after 1000 × g centrifugation. The pellet and
NE-Buffer A were mixed by gently pipetting and kept
on ice for 15 min. The mixture was then treated with 10%
NP-40, vortexed for 10 sec, and centrifuged at 10,000 × g
for 30 sec, 4°C. The supernatant was discarded and the
pellet was resuspended and homogenized in NE-Buffer B
(5 mmol/L HEPES, pH7.9, 26% Glycerol, 1.5 mmol/L
MgCl2, 0.2 mmol/L EDTA, 0.5 mmol/L DTT, 0.5 mmol/L
PMSF), and then centrifuged at 13,000 × g for 20 min, 4°C.
The supernatant was extracted as the nuclear fraction.
Western blot analysis
Equal amounts of proteins were size-fractionated using
SDS-polyacrylamide gel electrophoresis and electro-
transferred onto polyvinylidene difluoride transfer mem-
branes (Millipore). Blots were incubated for 1 hr at roomtemperature in 7% BSA for blocking, and proteins were
detected with primary antibodies overnight, and then
blotted with horseradish peroxidase conjugated second-
ary antibodies for 45 min. The immunoblots were visu-
alized using ECL (Millipore). The mouse monoclonal
antibody against cytochrome c was provided from ZYMED
Laboratories, Inc. (South San Francisco, CA, USA). All
other antibodies were purchased from Santa Cruz.
Xenograft assays in nude mice
The animal experiments were approved by the Commit-
tee on the Ethics of Animal Experiments of the Xiamen
University Medical College and carried out in the Animal
Research Center, Department of Basic Medicine. HepG2
cells (2 × 106) were implanted by subcutaneous injection
into the right foreleg of the female Balb/c nude mice.
The mice in the 3 treatment groups received intraperi-
toneal (i.p.) injections of 100 μL matrine at dose of 50,
75 or 100 mg/kg. Meanwhile, the mice in the negative
and positive groups received i.p. injection of 100 μL of
physiological saline and cyclophosphamide at 50 mg/kg,
respectively. The mice were monitored every day, weighed
before received i.p. injection of matrine, and killed 3 weeks
after treatment, and then the tumors were used to do
further experiments. Nine nude mice were used in each
group of experiment.
Immunohistochemical staining
Tumor tissue specimens were fixed in neutral formalin
and embedded in paraffin after collection from the killed
mice. Tissue Sections 5 μm thick were dewaxed and incu-
bated with 0.01 M natrium citricum for antigen retrieval.
The slides were rinsed in PBS and incubated overnight at
4°C with diluted anti-AIF antibodies. Following experi-
ments were performed using the immunostaining kit
according to the manufacturer’s instructions.
Statistic analysis
All data are showed as the means ± S.D. for at least three
separate determinations for each group. The differences
between the groups were examined for statistical signifi-
cance using the Student’s t-test with Prism 5 software.
Additional files
Additional file 1: Figure S1. Matrine induced caspase-dependent
and -independent cell death in HepG2 cells. (A) Cells were treated with
different concentrations of matrine (0, 0.25, 0.5, 1, 1.5, 2 mg/ml) for 24 hrs, or
1.0 mg/ml matrine for different time periods (0, 12, 24, 36, 48 hrs), and then
the cell death was determined by annexin V/PI staining assay. (B) Cells were
collected after treated with different concentration of matrine for 24 hrs and
analyzed for ΔΨm by Rh123 retention. (C) Effect of pancaspase inhibitor,
z-VAD-fmk, on matrine-induced cell death. HepG2 cells were pretreated
with z-VAD-fmk (20 μM, 2 hrs) before matrine treatment. Cell death was
analyzed by PI staining assay.
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siRNA (40 or 60 nM) or non-targeted siRNA for 24 hrs, and then treated
with matrine at 1.5 mg/ml for 24 hrs. Cells were stained with propidium
iodide (Annexin V/PI) to assess cell viability by flow cytometry.
Additional file 3: Figure S3. Bid mediated the cell death induced by
matrine, as an upstream regulator of AIF. HepG2 cells were transfected
with Bid siRNA (40 or 60 nM) or non-targeted siRNA for 24 hrs (A) or pre-
treated Bid inhibitor BI-6C9 (10 μM) for 1 hr (B), then treated with matrine
at 1.5 mg/ml for 24 hrs. Cells were stained with Annexin V/PI to assess
cell viability by flow cytometry.
Additional file 4: Figure S4. ROS production is required for AIF
activation in HepG2 cells. (A, B) Cells were treated with matrine at
different concentrations (0, 0.25, 0.5, 1, 1.5, 2 mg/ml) for 24 hrs or at
1.5 mg/ml for 24 hrs in the absence or presence of Tiron (5 μM), the ROS
scavenger. ROS levels were then detected by flow cytometry. (C) Tiron
significantly attenuated matrine-induced cell death as determined by
Annexin V/PI staining and flow cytometry.
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